UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 15, 2021
Biotech Acquisition Company
(Exact name of registrant as specified in its charter)
| Cayman Islands | | 001-39935 | | N/A |
(State or other jurisdiction
of incorporation) | | (Commission File Number) | | (IRS Employer
Identification No.) |
545 West 25th Street, 20th Floor
New York, NY 10001
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (212) 227-1905
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | | Trading Symbol(s) | | Name of each exchange on which
registered |
| | | | | |
| Units, each consisting of one Class A ordinary share, par value $0.0001 per share, and one-half of one redeemable warrant | | BIOTU | | The Nasdaq Stock Market LLC |
| | | | | |
| Class A ordinary shares, par value $0.001 per share, included as part of the units | | BIOT | | The Nasdaq Stock Market LLC |
| | | | | |
| Redeemable warrants included as part of the Units | | BIOTW | | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company þ
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
Separate Trading of Units, Class A Ordinary Shares and Warrants
On March 15, 2021, Biotech Acquisition Company (the “Company”) announced that, commencing on March 18, 2021, the holders of units issued in its initial public offering, each unit consisting of one Class A ordinary share of the Company, par value $0.0001 per share, and one-half of one warrant of the Company, each whole warrant entitling the holder thereof to purchase one Class A ordinary share for $11.50 per share, may elect to separately trade the Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The units not separated will continue to trade on the Nasdaq Capital Market under the symbol “BIOTU.” The Class A ordinary shares and the warrants are expected to trade on the Nasdaq Capital Market under the symbols “BIOT” and “BIOTW,” respectively. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into Class A common ordinary shares and warrants.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | BIOTECH ACQUISITION COMPANY |
| | | |
| Dated: March 15, 2021 | By: | /s/ Ivan Jarry |
| | | Name: Ivan Jarry |
| | | Title: Chief Operating Officer |
2
